Allarity Therapeutics Announces SPAC's Form S-1 Filing for Proposed IPO

What Happened Allarity Therapeutics, Inc. disclosed in an 8‑K (filed Sept 14, 2026) that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), publicly filed a Registration Statement on Form S‑1 with the U.S. Securities and Exchange Commission on September 11, 2026 relating to a proposed initial public offering of its units. The Company attached a press release dated September 11, 2026 as Exhibit 99.1 and incorporated it by reference.

Key Details

• Allarity Acquisition Corp. is described as a newly formed SPAC.
• Registration Statement: Form S‑1 filed with the SEC on September 11, 2026 for a proposed IPO of units.
• Allarity Therapeutics filed the Form 8‑K disclosing the S‑1 filing on September 14, 2026; press release provided as Exhibit 99.1.
• The 8‑K does not include offering terms, dollar amounts, or a timeline for the proposed IPO.

Why It Matters This filing is an early, formal step toward creating a public SPAC vehicle tied to Allarity’s activities. For investors, it signals a potential path to raise capital or pursue a business combination in the future, but it is not a completed transaction. Monitor subsequent SEC filings (e.g., S‑1 amendments, effectiveness notices, or proxy/transaction filings) for offering terms, proceeds, and any announced business combination or impact on Allarity’s strategy.